Biotech and Real Estate Lead a Broad Rally in Chinese Equities
TREE NEWS reports: Chinese equities opened higher on September 21, with the ChiNext Index climbing nearly 1% intraday as biopharmaceutical and real estate shares rallied sharply. The rally was driven by two major policy catalysts: a joint five-year plan for the pharmaceutical industry issued by the Ministry of Industry and Information Technology and nine other government departments on September 18, and new housing provident fund regulations that took effect on September 20. By midday, the Shanghai Composite was up 0.55%, the Shenzhen Component gained 0.57%, and the ChiNext Index rose 0.93%. Turnover across the Shanghai and Shenzhen markets reached 1.33 trillion yuan in the morning session, roughly flat versus the prior day. More than 4,300 stocks advanced.
Policy Catalysts: Innovation Drugs and Housing Support
The pharmaceutical plan targets world-leading biopharmaceutical R&D and applications by 2030, with systemic breakthroughs in core technologies. It explicitly sets an annual growth target of over 20% for the innovative drug sector and calls for the integration of artificial intelligence, quantum computing, and computational medicine into drug discovery. The new housing provident fund rules expand withdrawal scenarios from six to nine, adding home renovation and property management fees. Separate reports showed that existing-home transactions reached 550 million square meters in the first eight months of 2025, up 10.6% year-on-year and surpassing new-home sales, signaling a structural shift toward a stock-market era for Chinese real estate.
Market Implications: Sector Rotation and Policy-Driven Trades
The biotech surge was broad-based. Innovative drug developers, contract research organizations (CROs), medical services, and medical device makers all posted strong gains. Several stocks hit the 20% daily limit, including Novogene, Nearshore Protein, and Tellgen. Hong Kong-listed biotech names also soared, with the Hang Seng Biotech Index up nearly 5%. Analysts at multiple brokerages see the five-year plan as a clear signal that Beijing will prioritize innovation quality and global competitiveness, favoring leading innovative drug makers, CXO players, and AI-driven drug discovery platforms.
Real estate developers extended gains, with Greenland Holdings hitting its second consecutive daily limit and Vanke A rising over 7%. The provident fund changes and ongoing discussions about presale-to-completed-sale transition are seen as supportive for state-owned developers with strong balance sheets and delivery track records. Meanwhile, the Hang Seng Tech Index dipped 0.13% as AI hardware maker Lenovo fell over 5%, offsetting gains in Xiaomi, Tencent, and Alibaba. Semiconductor and consumer electronics names were mixed, while optical communication and PCB stocks rallied on AI infrastructure demand.
Key Takeaways for Investors
- Policy tailwinds are real: The pharma plan and housing fund changes provide concrete medium-term growth targets and demand support, making them more than short-term sentiment boosters.
- Watch the rotation: Capital is moving from semiconductors into biotech, real estate, and selected tech hardware. This rotation may persist if policy execution follows through.
- Global value realization in biotech: Chinese innovative drug makers are entering a phase where overseas licensing and product launches could drive earnings upgrades.
- Real estate remains a stock-picker’s market: The shift to existing-home dominance and completed-sale models favors financially strong state-owned developers over highly levered private peers.
- Rates and commodities: Government bond futures edged higher, reflecting expectations of continued monetary accommodation. Commodities were mixed, with lithium carbonate up 4% and crude oil down over 6%, highlighting divergent demand signals.
Investors should monitor follow-through on the pharma plan’s implementation details, local government housing fund adjustments, and whether the tech-heavy ChiNext can sustain momentum amid global AI hardware volatility.
